Global Human Liver Models Market - 2022-2029

Market Overview

Human Liver Models Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

The human liver model is a structure used to research the drug's potential for liver failure and other liver diseases. It allows for the improvement of knowledge regarding liver disease and complex spatial relations of the internal anatomy of the liver. Modern liver models consist of tiny organoids or mini-organs designed to mimic the physiology, anatomy, and activities of the human liver from the molecular level onward. These living models are a recent development in science that might displace animal models, and new medications are tested for liver damage using the human liver model.

Market Dynamics

Innovations in the human liver models for drug development are expected to drive market growth.

Drug-induced liver injury (DILI), a prominent factor in drug attrition, is partially accounted for by differences in the metabolic pathways between preclinical animals and humans. In vitro, human liver models are used in the biopharmaceutical sector to study relevant drug transport and metabolic systems, lower the risk of DILI, and study these mechanisms. However, liver cells can't be used to simulate the long-term effects of medications and disease stimuli since they lose their phenotypic properties in two-dimensional monocultures on collagen-coated polystyrene/glass within 1-3 days. Bioengineers have modified equipment from the semiconductor industry and additive manufacturing to precisely manipulate the microenvironment of liver cells to overcome this constraint. These tools have enabled the creation of cutting-edge two-dimensional and three-dimensional human liver platforms for various throughput requirements and assay endpoints (such as micropatterned cocultures, spheroids, organoids, bioprinted tissues, and microfluidic devices); these platforms have significantly improved liver functions closer to physiologic levels and improved functional lifetime to >4 weeks, which has translated to higher sensitivity for anticipating drug outcomes. For instance, Microfluidic devices can be constructed using microfabrication methods (such as soft lithography and 3D bioprinting), which can provide nutrients and remove waste products automatically while exposing cells to fluid shear pressures and gradients of soluble substances just as they would in vivo. Since it is biocompatible, optically transparent, reasonably priced, and suitable for rapid prototyping, polydimethylsiloxane (PDMS) is frequently used to create microfluidic devices. However, PDMS' hydrophobic and porous characteristics for drug screening applications can lead to the absorption of some lipophilic medications and media additives. Therefore, coating changes for PDMS or thermoplastic substitutes are being investigated for the next generation of microfluidic devices for cell culture in the drug development pipeline. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint

The issues in incorporating liver models into the current workflow and the high costs of human liver models, lack of skilled professionals and 3D infrastructure for cell culture-based research are factors the market is expected to get hampered in the forecast period.

Industry Analysis

The human liver models market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the market. Although coronaviruses have received much attention as respiratory tract infections, little is known about how they affect the hepatobiliary system. Overall, decreased albumin and increased aminotransferase and bilirubin levels are common signs of liver damage brought on by coronaviruses. Direct injury, immune-mediated injury, ischemia and hypoxia, thrombosis, and medication hepatotoxicity are just a few of the pathophysiological concepts that have been put forth. Due to the urgent need for COVID-19 treatments and protection against the SARS-COV-2 virus, new antiviral substances and vaccines are being produced in an unprecedented amount of time to shorten the time to market. Our drug testing facilities are currently fully operating.

Moreover, organizations developing novel drug and vaccine formulations request free safety evaluations utilizing preclinical liver models to spot any hazardous effects in humans. For instance, on March 24, 2020, InSphero AG announced that it would provide free safety testing for formulations of the coronavirus (SARS-COV-2) vaccine and experimental COVID-19 drugs. Any institution (academic, governmental, or industrial) that wishes to conduct risk assessments on its medicines under development may use the COVID-19 tests based on InSphero's 3D InSight Human Liver models. In contrast, the pandemic interrupts the supply chain. Thus, from the above statements, the market got affected. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Liver-on-a-chip segment is expected to hold the largest market share in human liver models market

The liver-on-a-chip segment accounted for the largest market share in 2021. The bioengineered systems known as liver-on-a-chip can emulate the essential elements of the liver's basic operation. Compared to other variants, liver-on-a-chip is simpler and less expensive. For instance, CN Bio Innovations, multi-well PhysioMimix Liver-on-a-Chip consumable plates are ideally suited to primary liver cell culture and co-culture assays. They enable researchers to identify liver toxicity markers, model liver disease and study drug metabolism. Moreover, the rising need for low-cost substitutes for animal models used in drug research and development, growing initiatives for liver organoids and technological developments in human organ modeling are the other factors the market segment holds the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global human liver models market

In 2021, the North America Human Liver Models accounted for the highest revenue share in the global market. The increasing prevalence of liver disorders and non-alcoholic fatty liver, technological advancements in the human liver models, increasing aid from governments and increasing investments and focus on tissue culture diagnostics are some of the factors the market is expected to boost in the forecast period. For instance, according to the American Liver Foundation, Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver condition in the United States. It's estimated that about 25 percent of adults in the U.S. have NAFLD. Consequently, there is a requirement for drug toxicity detection at an earlier stage which helps in minimizing the financial losses in the later stages. Hence, it has increased the demand for human liver models in the region.

Competitive Landscape

Major key players in the human liver models market are Emulate, Inc., InSphero, BioIVT, Organovo Holdings Inc., Kirkstall, Cyprio, CELLINK, MIMETAS BV, CN Bio Innovations, Thermo Fisher Scientific.

Emulate, Inc.:

Overview:

Emulate was established in 2014 and headquartered in the United States. It is a privately held company. It is the creator of a platform for automated bio-emulation that may be used to study endothelial and neuronal cells in a living, micro-engineered environment. The company's platform is a novel living system that mimics human biology to understand how various illnesses, medications, chemicals, and foods affect human health by fusing micro-engineering with living human cells, allowing doctors to gain in-depth insights from the human body and its cells.

Product Portfolio:

Liver-Chip: The quad-culture Emulate Liver-Chip combines four human cell types in a dynamic microenvironment to support in vivo like gene expression, functionality, and physiology. Applications include general and mechanistic toxicity evaluation, biomarker identification and mechanism of action determination.

The global human liver models market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.